TransMedics (TMDX) EBITDA (2018 - 2026)

TransMedics' EBITDA history runs 9 years deep, the most recent figure standing at $13.3 million for Q1 2026.

• In Q1 2026, EBITDA fell 51.55% year-over-year to $13.3 million; the TTM figure through Mar 2026 stood at $94.4 million (up 79.82% YoY), while the FY2025 annual figure was $108.6 million, up 189.59% from the prior year.
• EBITDA was $13.3 million for Q1 2026 at TransMedics, down from $21.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $36.6 million in Q2 2025 to a low of -$28.3 million in Q3 2023.
• Historically, EBITDA has averaged $5.8 million across 5 years, with a median of $3.9 million in 2024.
• The sharpest annual moves came in 2023 and 2024: EBITDA sank 411.09% in 2023, then jumped 1480.57% in 2024.
• A 5-year view of EBITDA shows it stood at -$6.8 million in 2022, then soared by 138.4% to $2.6 million in 2023, then soared by 232.08% to $8.6 million in 2024, then soared by 146.1% to $21.3 million in 2025, then tumbled by 37.49% to $13.3 million in 2026.
• The last three EBITDA figures came in at $13.3 million (Q1 2026), $21.3 million (Q4 2025), and $23.3 million (Q3 2025), per Business Quant data.